Quercetin-3'-O-Phosphate

Quercetin-3'-O-Phosphate

SCHEMBL118113

O=c1c(O)c(-c2ccc(O)c(OP(=O)(O)O)c2)oc2cc(O)cc(O)c12

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 8/20 0.73
MEN1 O00255 7/20 0.73
KMT2A Q03164 7/20 0.73
CYP1A1 P04798 7/20 0.73
CYP1B1 Q16678 7/20 0.73
XDH P47989 5/20 0.73
CA12 O43570 4/20 0.73
PPARG P37231 4/20 0.73
CA7 P43166 4/20 0.73
IPMK Q8NFU5 4/20 0.73
IP6K2 Q9UHH9 4/20 0.73
CA2 P00918 3/20 0.73
CA4 P22748 3/20 0.73
BCL9 O00512 9/20 0.67
CTNNB1 P35222 9/20 0.67
ABCB1 P08183 7/20 0.67
CYP3A4 P08684 5/20 0.67
CYP2C9 P11712 5/20 0.67
FTO Q9C0B1 5/20 0.67
KDM4E B2RXH2 4/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quercetin-3'-O-Phosphate SCHEMBL30299021 1.00 CYP1A2 (0.73) CYP1A2MEN1KMT2ACYP1A1CYP1B1
Quercetin-3'-O-Phosphate SCHEMBL30814958 1.00 CYP1A2 (0.73) CYP1A2MEN1KMT2ACYP1A1CYP1B1
SCHEMBL117682 0.91 CYP1A2 (0.73) CYP1A2MEN1KMT2ACYP1A1CYP1B1
SCHEMBL117527 0.91 CYP1A2 (0.73) CYP1A2MEN1KMT2ACYP1A1CYP1B1
SCHEMBL19197066 0.90 CYP1A2 (0.65) CYP1A2MEN1KMT2ACYP1A1CYP1B1
SCHEMBL19470004 0.86 CYP1A2 (0.72) CYP1A2MEN1KMT2ACYP1A1CYP1B1
SCHEMBL3755551 0.85 MEN1 (0.69) CYP1A2MEN1KMT2ACYP1A1CYP1B1
Quercetin SCHEMBL4473370 0.85 MEN1 (0.74) CYP1A2MEN1KMT2ACYP1A1CYP1B1
SCHEMBL16984539 0.85 MEN1 (0.74) CYP1A2MEN1KMT2ACYP1A1CYP1B1
SCHEMBL3807701 0.84 CYP1A2 (0.71) CYP1A2MEN1KMT2ACYP1A1CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2355814-A2 PYRONES FOR THE TREATMENT OF METABOLIC DISORDERS Limerick BioPharma, Inc. (US) 2011-08-17 EP claimed
US-7947733-B2 Phosphorylated pyrone analogs and methods LIMERICK BIOPHARMA (US) 2011-05-24 US claimed
US-20110028437-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS LIMERICK BIOPHARMA, INC. (US) 2011-02-03 US claimed
US-20100204089-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS LIMERICK BIOPHARMA, INC. 2010-08-12 US claimed
WO-2010042886-A2 PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-04-15 WO claimed
US-20090069273-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS LIMERICK BIOPHARMA, INC. 2009-03-12 US claimed
CN-117320713-A Certain fascin-binding compounds for dendritic spine production 斯皮诺吉尼克斯公司 2023-12-29 CN disclosed
EP-2424541-A2 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT Limerick BioPharma, Inc. (US) 2012-03-07 EP disclosed
EP-2355814-A2 PYRONES FOR THE TREATMENT OF METABOLIC DISORDERS Limerick BioPharma, Inc. (US) 2011-08-17 EP disclosed
US-7947733-B2 Phosphorylated pyrone analogs and methods LIMERICK BIOPHARMA (US) 2011-05-24 US disclosed
US-20110028437-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS LIMERICK BIOPHARMA, INC. (US) 2011-02-03 US disclosed
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-11-25 US disclosed
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-11-25 US disclosed
WO-2010042886-A2 PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-04-15 WO disclosed
US-20090325906-A1 Methods and compositions for therapeutic treatment LIMERICK BIOPHARMA, INC. 2009-12-31 US disclosed
US-20090325906-A1 Methods and compositions for therapeutic treatment LIMERICK BIOPHARMA, INC. 2009-12-31 US disclosed
WO-2009158031-A2 METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2009-12-30 WO disclosed
WO-2009158007-A2 METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2009-12-30 WO disclosed
US-20090069273-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS LIMERICK BIOPHARMA, INC. 2009-03-12 US disclosed
WO-2009018338-A2 PHOSPHORYLATED PYRONE ANALOGS AND METHODS LIMERICK BIOPHARMA, INC. (US) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069273-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS PCK1, PC, PCK2 CYP1A2 832/4885MEN1 4072/4885KMT2A 3401/4885
US-20090325906-A1 Methods and compositions for therapeutic treatment SLC2A1, SLC2A2, SLC2A3 CYP1A2 3381/4885MEN1 4409/4885KMT2A 4599/4885
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT PC, PCK1, PYGL CYP1A2 2311/4885MEN1 2302/4885KMT2A 4512/4885
US-20110028437-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS PCK1, PC, PCK2 CYP1A2 832/4885MEN1 4072/4885KMT2A 3401/4885
US-20100204089-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS PCK1, PC, PCK2 CYP1A2 832/4885MEN1 4072/4885KMT2A 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.